Galmed Pharmaceuticals
GLMD
24 hedge funds and large institutions have $7.05M invested in Galmed Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 7 closing their positions.
0.01% less ownership
Funds ownership: 0.09% → 0.09% (-0.01%)
8% less funds holding
Funds holding: 26 → 24 (-2)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
40% less capital invested
Capital invested by funds: $11.8M → $7.05M (-$4.75M)
88% less call options, than puts
Call options by funds: $51K | Put options by funds: $429K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$223K |
| 2 |
Millennium Management
New York
|
+$101K |
| 3 |
VF
Virtu Financial
New York
|
+$90.3K |
| 4 |
LC
Lindbrook Capital
Calabasas,
California
|
+$28.9K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$18.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
-$800K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$193K |
| 3 |
Rockefeller Capital Management
New York
|
-$98K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$78K |
| 5 |
Squarepoint
New York
|
-$71K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citadel Advisors
Miami,
Florida
| – | -$78K | -156 | Closed |
|
|
27
Squarepoint
New York
| – | -$71K | -141 | Closed |
|
|
TI
28
Tidal Investments
Milwaukee,
Wisconsin
| – | -$69K | -137 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$5K | -10 | Closed |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3K | -6 | Closed |
|
|
SPIA
31
Steward Partners Investment Advisory
New York
| – | -$1K | -3 | Closed |
|
GLMD Hedge Fund Activity: Q4 2021 in Review
24 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2021, worth a combined $7.05M — down 40% from $11.8M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GLMD and 5 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Susquehanna International Group, adding an estimated $223K. The largest seller was Ibex Investors, cutting an estimated $800K.
- 24 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2021, down from 26 in Q3 2021.
- Funds reported $7.05M of Galmed Pharmaceuticals stock for Q4 2021, down 40% quarter-over-quarter.
- 5 funds opened new Galmed Pharmaceuticals positions in Q4 2021 and 7 closed out, a net change of -2 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2021 was Susquehanna International Group, an estimated $223K added.
- The largest Galmed Pharmaceuticals seller in Q4 2021 was Ibex Investors, an estimated $800K sold.
Based on aggregated 13F filings for Q4 2021.